according to the manufacturer's instructions. The simple sequence length polymorphism in the promoter of ALOX5 (rs59439148) was genotyped as previously 
Urinary leukotriene E 4
Urine samples were obtained from children immediately following sputum induction and stored on ice until transfer to storage at -80 o C within 1 h. Analysis was by gas chromatography-mass spectrometry using negative ion chemical ionisation (GC- Bacharier) . Original data were not received from the study of Valovirta and colleagues 4 which included children aged six months to five years, and reported a secondary outcome for "adjusted rate of asthma attacks", with an attack defined within the statement; "the start of an asthma attack was the first day the patient's symptoms required HRU". Overall, the 3 studies were comparable in terms of study design (placebo-controlled trial), randomisation, concealment of allocation, inclusion criteria and duration of follow-up (12 months) to those in this report (Supplementary Table 7) .
NICI-MS
A meta-analysis was performed using the inverse variance fixed effect method to calculate the summary weighted difference between the means with 95% confidence intervals. The analysis was performed using RevMan version 5.3 6 . We compared the mean (SD) for number of episodes requiring an unscheduled medical attention per child in each study, comparing experimental (intermittent montelukast) and control (placebo) groups, using a fixed effects model for mean difference as per the review by OR; odds ratio, IRR incidence rate ratio. wheeze with and without viral colds, Episodic wheeze; wheeze only with colds Table S8 . Relationship of adverse events to study medication. The pooled summary (diamond) represents the overall result, with the vertical line representing no overall effect (weighted mean difference=0). There is no benefit of intermittent montelukast in an unselected population of children with preschool wheeze (test for overall effect, p=0·21). Nwokoro 2014 refers to the current study
Montelukast Placebo

